// App-Quantinova.ai

4908 : Cancer immunotherapy with immunomodulatory anti-CD137 and anti-PD-1 monoclonal antibodies requires Batf3-dependent dendritic cells

Researchers

Presenter

  • Alfonso R. Sanchez-Paulete

Principal Investigators

  • Francisco J. Cueto

  • Maria Martinez-Lopez

  • Sara Labiano

  • Aizea Morales-Kastresana

  • Maria E. Rodriguez-Ruiz

  • Maria Jure-Kunkel

  • Arantza Azpilikueta

  • Jose I. Quetglas

  • David Sancho

  • Ignacio Melero

Medical Centers

  • Center for Applied Medical Research, Pamplona, Spain

  • Centro Nacional de Investigaciones Cardiovasculares, Madrid, Spain.

  • University of Navarra, Pamplona, Spain

  • Bristol-Myers Sqiubb, Princeton, NJ

Locations

  • United States

  • Spain

Companies

  • Bristol-Myers Squibb

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Melanoma

  • Solid malignancies

Biomarkers

  • N/A

Drug/Treatment

  • Poly-ICLC

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved